Cumberland Pharmaceuticals Expands Vibativ Access with Vizient
Cumberland Pharmaceuticals Expands Vibativ Access with Vizient
Cumberland Pharmaceuticals Inc., a leading specialty pharmaceutical company dedicated to enhancing patient care, has made significant strides in its mission. The company recently announced a new contract that introduces the Vibativ (telavancin) 4-Vial Starter Pak to Vizient members, improving treatment options across the country.
Understanding Vizient's Role in Healthcare
Vizient serves a vast network of healthcare providers, making up an impressive 65% of the nation's acute care facilities and supporting 97% of academic medical centers. This robust infrastructure means that through this contract, Vibativ's new configuration will be more readily available, offering healthcare professionals essential tools for initiating treatment in both inpatient and outpatient settings.
What is Vibativ?
Vibativ is an FDA-approved injectable antibiotic designated for treating serious bacterial infections, particularly hospital-acquired and ventilator-associated pneumonia (HABP/VABP). It also addresses complicated skin and skin structure infections caused by Gram-positive pathogens, including the challenging methicillin-resistant Staphylococcus aureus (MRSA).
Flexible Treatment Options for Patients
The introduction of the 4-Vial Starter Pak allows healthcare providers to initiate treatment promptly and efficiently. Cumberland's CEO, A.J. Kazimi, expressed enthusiasm about this expansion, remarking on the importance of enhancing availability of their potent antibiotic. With this increased access, Vizient-contracted providers can deliver cost-effective treatment in various healthcare environments, including hospitals and outpatient infusion centers.
Enhanced Product Lineup
In addition to the new 4-Vial Starter Pak, Vibativ is also available in a 12-vial carton for Vizient clients. This diverse offering of packaging aims to cater to the varied needs of healthcare providers, ensuring they have what they need to manage serious infections effectively.
Clinical Efficacy of Vibativ
Recent clinical studies underscore Vibativ's effectiveness in treating infections unmet by other antibiotics. The product has been shown to significantly elevate cure rates when compared with traditional treatments such as vancomycin, particularly in cases where patients suffer from HABP/VABP. This efficacy is crucial, as Gram-positive bacterial infections often present considerable treatment challenges.
The Importance of Available Options
With Vibativ, Cumberland Pharmaceuticals has positioned itself as a strong contender in the antibiotics market. The inclusion of its products in large healthcare networks, especially through providers like Vizient, enhances its visibility and accessibility. This strategic partnership reflects Cumberland's commitment to improve healthcare delivery and patient outcomes on a national scale.
Looking Ahead for Cumberland Pharmaceuticals
As Cumberland Pharmaceuticals continues to innovate and expand its product offerings, the company remains focused on improving the quality of patient care. Alongside Vibativ, its portfolio includes several FDA-approved treatments targeting various acute care challenges such as acetaminophen poisoning and postoperative nausea. All evidence indicates that the future is bright for Cumberland as it addresses critical gaps in pharmacological treatment.
Increased Awareness and Education Initiatives
The company is not only dedicated to product development; it also prioritizes education about their offerings. For medical professionals seeking more information about Vibativ or other products, Cumberland invites inquiries directed to its Medical Affairs team, ensuring that healthcare providers are equipped with the necessary knowledge to offer effective treatments.
Frequently Asked Questions
What is the significance of the Vizient contract for Vibativ?
The Vizient contract allows increased access to Vibativ through a broader network of healthcare providers, facilitating better treatment options.
What types of infections does Vibativ treat?
Vibativ is used primarily for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin and skin structure infections.
How does Vibativ compare to traditional antibiotics?
Clinical studies show Vibativ achieves higher cure rates than traditional treatments like vancomycin for certain Gram-positive infections.
Who should be contacted for medical inquiries about Vibativ?
Cumberland Pharmaceuticals encourages healthcare providers to reach out to their Medical Affairs team for questions or additional information.
Does Cumberland Pharmaceuticals have more products in development?
Yes, the company is actively involved in clinical studies for additional treatments that address various health conditions, showcasing their ongoing commitment to patient care.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
